Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study)

BACKGROUND: Nivolumab, the anti-programmed cell death protein 1 antibody, has been approved for advanced melanoma, mainly based on evidence from Western countries. The profile of melanoma differs between Caucasian and Asian patients. This study was performed to obtain post-marketing data of nivoluma...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Naoya, Takenouchi, Tatsuya, Nakamura, Yasuhiro, Takahashi, Akira, Namikawa, Kenjiro, Kitano, Shigehisa, Fujita, Tomonobu, Kubota, Kazumi, Yamanaka, Takeharu, Kawakami, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326387/
https://www.ncbi.nlm.nih.gov/pubmed/34115870
http://dx.doi.org/10.1093/jjco/hyab064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326387/
https://www.ncbi.nlm.nih.gov/pubmed/34115870
http://dx.doi.org/10.1093/jjco/hyab064

Ejemplares similares